Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 15/20 | 0.64 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | LDLR | P01130 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.51 |
| ▸ | RAF1 | P04049 | 2/20 | 0.50 |
| ▸ | BRAF | P15056 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29874680 | 1.00 | NR2E1 (0.64) | NR2E1CSF1RLDLRKITPCSK9 | |
| SCHEMBL17134906 | 0.88 | NR2E1 (0.62) | NR2E1CSF1RRAF1BRAFKDM4E | |
| SCHEMBL1912794 | 0.88 | NR2E1 (0.65) | NR2E1CSF1RRAF1BRAFKDM4E | |
| SCHEMBL12171374 | 0.86 | NR2E1 (0.63) | NR2E1CSF1RLDLRKITPCSK9 | |
| SCHEMBL22745768 | 0.86 | NR2E1 (0.63) | NR2E1CSF1RLDLRKITPCSK9 | |
| SCHEMBL18239969 | 0.86 | NR2E1 (0.63) | NR2E1CSF1RLDLRKITPCSK9 | |
| SCHEMBL28425790 | 0.85 | NR4A1 (0.47) | NR2E1LDLRPCSK9KDM4EPOLB | |
| SCHEMBL22745766 | 0.85 | NR2E1 (0.62) | NR2E1CSF1RRAF1BRAFKDM4E | |
| SCHEMBL15381980 | 0.84 | NR2E1 (0.61) | NR2E1CSF1RLDLRKITPCSK9 | |
| SCHEMBL12154454 | 0.83 | NR2E1 (0.60) | NR2E1CSF1RLDLRKITPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722212-A1 | NOVEL COMPOUND FOR INHIBITING PROTEIN KINASES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Magicbullettherapeutics Co., Ltd. (KR) | 2026-04-08 | — | — | EP | disclosed |
| EP-4313292-B1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | CHIESI FARM SPA (IT) | 2026-02-18 | — | — | EP | disclosed |
| EP-4313972-B1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARM SPA (IT) | 2025-01-29 | — | — | EP | disclosed |
| US-20240308994-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2024-09-19 | — | — | US | disclosed |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-07-04 | — | — | US | disclosed |
| US-20240190847-A1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-13 | — | — | US | disclosed |
| EP-4313972-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313292-A1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023183444-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183470-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| WO-2006067445-A2 | CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| EP-1658290-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-24 | — | — | EP | disclosed |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-10-06 | — | — | US | disclosed |
| US-20050159391-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-07-21 | — | — | US | disclosed |
| EP-1546127-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | Novartis AG (CH) | 2005-06-29 | — | — | EP | disclosed |
| EP-1532138-A1 | INHIBITORS OF TYROSINE KINASES | Novartis AG (CH) | 2005-05-25 | — | — | EP | disclosed |
| WO-2005039486-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-05-06 | — | — | WO | disclosed |
| WO-2004029038-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004005281-A1 | INHIBITORS OF TYROSINE KINASES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190847-A1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | DDR1, DDR2, DDRGK1 | NR2E1 88/4885CSF1R 593/4885LDLR 388/4885 |
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | TYMP, NME2, DPYD | NR2E1 2847/4885CSF1R 3080/4885LDLR 4514/4885 |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | DDR1, DDR2, DDRGK1 | NR2E1 362/4885CSF1R 1126/4885LDLR 49/4885 |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | BMX, FES, FRK | NR2E1 1711/4885CSF1R 453/4885LDLR 971/4885 |
| US-20050159391-A1 | Compounds and compositions as protein kinase inhibitors | LCK, FYN, BMX | NR2E1 2028/4885CSF1R 915/4885LDLR 2583/4885 |
| US-20240308994-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | CSF1R, CSF3R, IL15RA | NR2E1 1971/4885CSF1R 1/4885LDLR 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.